Relief Therapeutics Holding AG (RLFTF)

[tcm55]

?"NeuroRX has developed two main treatments. The first, called Zyesami is designed to treat respiratory failure in the advanced and most difficult stages of Covid. The drug is in Phase III clinical trials and the company plans submitting it for US Food and Drug Administration (FDA) emergency approval before the trial is completed. The aim is to file for approval in about one month. Swiss company Relief Therapeutics, which has partnered NeurRX in developing the drug, is traded on the Swiss stock market with a market cap of about $700 million.

In a trial, the company was asked to show a reduction in mortality from coronavirus due to its drug but was unable to demonstrate this among a group of patients although it did succeed in reducing the number of days spent in hospital, and effectiveness in other parameters such as the number of days to recover. The company is now conducting a trial of the drug on less seriously ill patients.?"

Dr JJ... 31 May 2021 ?
https://iglob.es/?en1372702